Clinical Trial Update: Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML) [Phase 1]

View source ↗

Summary

Phase I/II open-label dose-escalation study of AZD4877 in acute myeloid leukemia was terminated; results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZD4877

Snippet

Sponsor: AstraZeneca | Conditions: Acute Myelogenous Leukemia | Phase 1 | Status: TERMINATED | Results posted: 2010-08-17